CFO departure
Valion Bio, Inc. discloses CFO departure: Lisa Wolf
Valion Bio, Inc. reported in a Form 8-K filed November 5, 2026 a change involving its Chief Financial Officer, Lisa Wolf, effective December 11, 2026. The filing's own words are quoted below.
In the filing's words
On October 31, 2026, Lisa Wolf notified the Special Committee of the Board of Directors of Valion Bio, Inc. (the “Company”) of her decision to voluntarily resign from her positions as President, Chief Operating Officer and Chief Financial Officer of the Company. Ms. Wolf’s resignation from each of these positions will become effective on December 11, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Valion Bio, Inc. (VBIO) |
|---|---|
| Event | Departure |
| Outgoing | Lisa Wolf |
| Effective | December 11, 2026 |
| 8-K filed | November 5, 2026 |
| SEC CIK | 0001787740 |
Valion Bio, Inc. reported this change in a Form 8-K, Item 5.02, filed November 5, 2026. The filing's own words are quoted above.
Also filed in November 2026
Other CFO moves on the record that month. All moves.
3 days ago· 2026-11-06DeparturePSIX
Power Solutions International, Inc. discloses CFO departure: Xun (Ken) Li
4 days ago· 2026-11-05InterimSSTK
Shutterstock, Inc. names Scott Grossman interim CFO
4 days ago· 2026-11-05TransitionTEAD
Teads Holding Co. CFO transition: Michael Coyle to succeed Jason B. Kiviat
4 days ago· 2026-11-05TransitionPNC
The PNC Financial Services Group, Inc. CFO transition: Alexander E. C. Overstrom to succeed Robert Q. Reilly
4 days ago· 2026-11-05InterimTRU
TransUnion names David Gilbert interim CFO
5 days ago· 2026-11-04TransitionCRTD
Creatd, Inc. CFO transition: Claudia Albelais to succeed Jeremy Frommer
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-11-05
Something wrong about Lisa Wolf? Send a correction with the primary source.